4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Nxera Pharma Co., Ltd. (4565) operates in the Biotechnology industry and is headquartered in Minato, Japan with about 322 employees. Its market capitalization is roughly JPY 85 billion. In the fiscal year ended 2025-12-31, 4565 reported JPY 29.6B in revenue and (JPY 12.5B) in net income.
Nxera Pharma Co., Ltd. operates as a biopharmaceutical company, engages in drug discovery and development in Japan, the United States, Germany, Switzerland, Bermuda, the United Kingdom, and internationally.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | JPY 29.6B | JPY 28.8B | JPY 12.8B | JPY 15.6B | — |
| Gross Profit | JPY 21.4B | JPY 21.2B | JPY 9.7B | JPY 14.6B | — |
| Operating Income (EBIT) | (JPY 8.5B) | (JPY 5.4B) | (JPY 9.5B) | JPY 3.4B | — |
| Net Income | (JPY 12.5B) | (JPY 4.8B) | (JPY 7.2B) | JPY 382M | — |
JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | JPY 134.8B | JPY 151.5B | JPY 157.2B | JPY 99.4B | — |
| Total Liabilities | JPY 73.8B | JPY 83.0B | JPY 90.4B | JPY 41.5B | — |
JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 4565 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms